Successful therapy of visceral leishmaniasis with curdlan involves T-helper 17 cytokines

Journal of Infectious Diseases

Volumn 207, Issue 6, 2013, Pages 1016-1025

  Ghosh, Kuntal ^a   Sharma, Gunjan ^b   Saha, Amrita ^a   Kar, Susanta ^b   Das, Pijush K ^b   Ukil, Anindita ^a  

^a UNIVERSITY OF CALCUTTA   (India)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

curdlan; nitric oxide; Th17 cytokines; visceral leishmaniasis

Indexed keywords

CURDLAN; CYTOKINE; DECTIN 1; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GIEMSA STAIN; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; LIVER; MACROPHAGE; MOUSE; NONHUMAN; PARASITE CLEARANCE; PARASITE LOAD; PARASITEMIA; PRIORITY JOURNAL; PROMASTIGOTE; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN; SPLEEN WEIGHT; TH1 CELL; TH17 CELL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BETA-GLUCANS; DISEASE MODELS, ANIMAL; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; INTERLEUKIN-1; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-23; INTERLEUKINS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MICE; MICE, INBRED BALB C; NITRIC OXIDE; TH1 CELLS; TH17 CELLS;

EID: 84874253704     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis771     Document Type: Article

References (48)

1. Diefenbach A, Schindler H, Rollinghoff M, Yokoyama WM, Bogdan C. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity. Science 1999; 284:951-5.
2. Engwerda CR, Murphy ML, Cotterell SE, Smelt SC, Kaye PM. Neutralization of IL-12 demonstrates the existence of discrete organspecific phases in the control of Leishmania donovani. Eur J Immunol 1998; 28:669-80.
3. Pitta MG, Romano A, Cabantous S, et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest 2009; 119:2379-87.
4. Ruddy MJ, Shen F, Smith JB, Sharma A, Gaffen SL. Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment. J Leukoc Biol 2004; 76:135-44.
5. Laan M, Cui ZH, Hoshino H, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162:2347-52.
6. Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8:369-77.
7. Loures FV, Pina A, Felonato M, Calich VL. TLR2 is a negative regulator of Th17 cells and tissue pathology in a pulmonary model of fungal infection. J Immunol 2009; 183:1279-90.
8. Kelly MN, Kolls JK, Happel K, et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun 2005; 73:617-21.
9. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445:648-51.
10. Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity 2004; 21:241-54.
11. Boniface K, Bernard FX, Garcia M, et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005; 174:3695-702.
12. Alcorn JF, Crowe CR, Kolls JK. TH17 cells in asthma and COPD. Annu Rev Physiol 2010; 72:495-516.
13. McGeachy MJ, Cua DJ. The link between IL-23 and Th17 cell-mediated immune pathologies. Semin Immunol 2007; 19:372-6.
14. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278:1910-4.
15. Khader SA, Gopal R. IL-17 in protective immunity to intracellular pathogens. Virulence 2010; 1:423-7.
16. Werner JL, Gessner MA, Lilly LM, et al. Neutrophils produce interleukin 17A (IL-17A) in a dectin-1-and IL-23-dependent manner during invasive fungal infection. Infect Immun 2011; 79:3966-77.
17. BeMiller JN, Bohn JN. (1→3)-β-D-Glucans as biological response modifiers: a review of structure-functional activity. Carbohydr Polym 1995; 28:3-14.
18. Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology 1999; 42:61-74.
19. Goodridge HS, Wolf AJ, Underhill DM. Beta-glucan recognition by the innate immune system. Immunol Rev 2009; 230:38-50.
20. Dennehy KM, Brown GD. The role of the beta-glucan receptor dectin-1 in control of fungal infection. J Leukoc Biol 2007; 82:253-8.
21. Agrawal S, Gupta S, Agrawal A. Human dendritic cells activated via dectin-1 are efficient at priming Th17, cytotoxic CD8 T and B cell responses. PLoS One 2010; 5:e13418.
22. Mukherjee S, Das L, Koley L, et al. Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis. J Infec Dis 2004; 189: 1024-34.
23. Ephros M, Waldman E, Zilberstein D. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob Agents Chemother 1997; 41:1064-8.
24. Murray HW, Miralles GD, Stoeckle MY, McDermott DF. Role and effect of IL-2 in experimental visceral leishmaniasis. J Immunol 1993; 151:929-38.
25. Banerjee A, De M, Ali N. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J Immunol 2008; 181:1386-98.
26. Ukil A, Biswas A, Das T, Das PK. 18 Beta-glycyrrhetinic acid triggers curative Th1 response and nitric oxide up-regulation in experimental visceral leishmaniasis associated with the activation of NF-kappa B. J Immunol 2005; 175:1161-9.
27. Ukil A, Kar S, Srivastav S, Ghosh K, Das PK. Curative effect of 18beta-glycyrrhetinic acid in experimental visceral leishmaniasis depends on phosphatase-dependent modulation of cellular MAP kinases. PLoS One 2011; 6:e29062.
28. Kar S, Ukil A, Sharma G, Das PK. MAPK-directed phosphatases preferentially regulate pro-and anti-inflammatory cytokines in experimental visceral leishmaniasis: involvement of distinct protein kinase C isoforms. J Leukoc Biol 2010; 88:9-20.
29. Ferwerda G, Meyer-Wentrup F, Kullberg BJ, Netea MG, Adema GJ. Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. Cell Microbiol 2008; 10:2058-66.
30. Chirigos MA. Immunomodulators: current and future development and application. Thymus 1992; 19(Suppl 1):S7-20.
31. Bhattacharjee S, Gupta G, Bhattacharya P, et al. Quassin alters the immunological patterns of murine macrophages through generation of nitric oxide to exert antileishmanial activity. J Antimicrob Chemother 2009; 63:317-24.
32. Ljungman AG, Leanderson P, Tagesson C. (1→3)-beta-d-Glucan stimulates nitric oxide generation and cytokine mRNA expression in macrophages. Environ Toxicol Pharmacol 1998; 5:273-81.
33. Evans SG, Morrison D, Kaneko Y, Havlik I. The effect of curdlan sulphate on development in vitro of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1998; 92:87-9.
34. Jagodzinski PP, Wiaderkiewicz R, Kurzawski G, et al. Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in vitro. Virology 1994; 202:735-45.
35. Vouldoukis I, Drapier JC, Nussler AK, et al. Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the L-arginine nitric oxide pathway. Antimicrob Agents Chemother 1996; 40:253-6.
36. Wilke CM, Bishop K, Fox D, Zou W. Deciphering the role of Th17 cells in human disease. Trends Immunol 2011; 32:603-11.
37. Moreira AP, Cavassani KA, Ismailoglu UB, et al. The protective role of TLR6 in a mouse model of asthma is mediated by IL-23 and IL-17A. J Clin Invest 2011; 121:4420-32.
38. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008; 38:2636-49.
39. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118:534-44.
40. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27:647-59.
41. Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008; 14:282-9.
42. Munoz M, Heimesaat MM, Danker K, et al. Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrix metalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med 2009; 206:3047-59.
43. McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007; 8:1390-7.
44. Reinhard K, Huber M, Wostl C, et al. c-Rel promotes type 1 and type 17 immune responses during Leishmania major infection. Eur J Immunol 2011; 41:1388-98.
45. Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012; 135:112-24.
46. Rong C, Hu W, Wu FR, Cao XJ, Chen FH. Interleukin-23 as a potential therapeutic target for rheumatoid arthritis. Mol Cell Biochem 2012; 361:243-8.
47. Ryan C, Abramson A, Patel M, Menter A. Current investigational drugs in psoriasis. Expert Opin Investig Drugs 2012; 21:473-87.
48. Zielinski CE, Mele F, Aschenbrenner D, et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012; 484:514-8.